已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy of Controlled-Release Paroxetine in the Treatment of Late-Life Depression

帕罗西汀 安慰剂 临床终点 萧条(经济学) 内科学 重性抑郁障碍 晚年抑郁症 医学 随机对照试验 心理学 精神科 抗抑郁药 海马结构 经济 病理 替代医学 宏观经济学 扁桃形结构 海马体
作者
Mark Hyman Rapaport,Lon S. Schneider,David L. Dunner,J. Davies,Cornelius D. Pitts
出处
期刊:The Journal of Clinical Psychiatry [Physicians Postgraduate Press, Inc.]
卷期号:64 (9): 1065-1074 被引量:97
标识
DOI:10.4088/jcp.v64n0912
摘要

Depression is the second most common neuropsychiatric disorder in older Americans, with significant clinical and public health costs. Despite advances in treatment, late-life depression remains a clinical challenge. Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition.In this 12-week, multicenter, placebo-controlled, flexible-dose, double-blind, randomized trial, 319 elderly patients (mean age = 70 years) were treated with controlled-release paroxetine (paroxetine CR) up to 50 mg/day (N = 104), immediate-release paroxetine (paroxetine IR) up to 40 mg/day (N = 106), or placebo (N = 109). Patients met DSM-IV criteria for major depressive disorder and had a total score of 18 or more on the 17-item Hamilton Rating Scale for Depression (HAM-D). The primary efficacy measure was change from baseline to endpoint in HAM-D total score.The primary efficacy analysis showed an adjusted difference between change from baseline in HAM-D score for paroxetine CR and placebo of -2.6 (95% confidence interval [CI] = -4.47 to -0.73, p = .007) at the week 12 last-observation-carried-forward (LOCF) endpoint. The adjusted difference between paroxetine IR and placebo was -2.8 (95% CI = -4.65 to -0.99, p = .003) at week 12. Paroxetine CR and IR were more effective than placebo, with mean +/- SD endpoint HAM-D total scores of 10.0 +/- 7.41 and 10.0 +/- 7.10, respectively, for the active treatments compared with 12.6 +/- 7.34 for placebo. Response, defined as a score of 1 or 2 on the Clinical Global Impressions-global improvement scale, was achieved by 72% of paroxetine CR patients (LOCF; p < .002 vs. placebo), 65% of paroxetine IR patients (p = .06 vs. placebo), and 52% of placebo patients. Remission, defined as a HAM-D total score < or = 7, was achieved by 43% of paroxetine CR patients (LOCF; p = .009 vs. placebo), 44% of paroxetine IR patients (p = .01 vs. placebo), and 26% of placebo patients. In a post hoc analysis, mean HAM-D improvement for paroxetine CR and paroxetine IR was greater than for placebo in both chronically depressed patients (duration > 2 years) and those with short-term (< or = 2 years) depression. Dropout rates due to adverse events were 12.5% for paroxetine CR, 16.0% for paroxetine IR, and 8.3% for placebo.Paroxetine CR and paroxetine IR are effective and well tolerated treatments for major depressive disorder in elderly patients, including those with chronic depression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
山有树完成签到 ,获得积分10
2秒前
云梦泽完成签到 ,获得积分10
4秒前
4秒前
allover完成签到,获得积分10
11秒前
judy发布了新的文献求助10
11秒前
12秒前
多鱼完成签到,获得积分10
13秒前
19秒前
jamesmo发布了新的文献求助30
20秒前
yu完成签到 ,获得积分10
21秒前
jcz完成签到,获得积分10
22秒前
23秒前
科研通AI6.4的应助被微解感染采纳,获得10
23秒前
JIE完成签到,获得积分10
27秒前
孤独的万恶完成签到 ,获得积分10
32秒前
Xi发布了新的文献求助60
33秒前
ni完成签到 ,获得积分20
33秒前
友好灵阳完成签到 ,获得积分10
34秒前
无花果的应助被2567285426采纳,获得10
35秒前
jamesmo完成签到,获得积分10
35秒前
yueqi完成签到,获得积分10
36秒前
愉快的真的应助被屈屈采纳,获得100
36秒前
铁打的雨点完成签到,获得积分10
37秒前
38秒前
小马完成签到,获得积分10
39秒前
zyyyyyy发布了新的文献求助10
39秒前
syvshc的应助被微解感染采纳,获得10
39秒前
合适雨完成签到,获得积分10
40秒前
dudu完成签到 ,获得积分10
41秒前
wanci的应助被lSj采纳,获得10
41秒前
sshuo发布了新的文献求助10
42秒前
言默完成签到,获得积分20
43秒前
趣多多发布了新的文献求助10
43秒前
45秒前
45秒前
何在完成签到,获得积分10
46秒前
52秒前
BugerKing完成签到 ,获得积分10
53秒前
molihuakai的应助被徐XU采纳,获得10
54秒前
悦耳芝完成签到 ,获得积分10
55秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194853
求助须知:如何正确求助?哪些是违规求助? 9580631
关于积分的说明 21872074
捐赠科研通 7794509
什么是DOI,文献DOI怎么找? 3437779
关于科研通互助平台的介绍 2561109
邀请新用户注册赠送积分活动 2484488